


## Interferon-free, tailored Tx beneficial in HCV-associated MC

August 16 2016



(HealthDay)—Interferon-free direct-acting antiviral (DAA) therapy is



beneficial for hepatitis C virus (HCV)-associated mixed cryoglobulinemia (MC) vasculitis, according to a study published online Aug. 2 in *Hepatology*.

Laura Gragnani, Ph.D., from the University of Florence in Italy, and colleagues conducted a prospective evaluation of the efficacy and safety of sofosbuvir-based DAA therapy, individually tailored according to the latest guidelines. The evaluation was conducted in a cohort of 44 patients with HCV-associated MC.

The researchers found that MC had evolved into an indolent lymphoma with monoclonal B cell lymphocytosis in two patients. All patients had negative HCV viremia at weeks 12 and 24 post-treatment; all had clinical response of vasculitis at this point. There were significant decreases in the mean Birmingham Vasculitis Activity Score from baseline through 24 weeks; significant decreases were also seen in the mean cryocrit value. Partial clinical response of vasculitis and about a 50 percent decrease of cryocrit were seen in the two patients with MC and lymphoma, although none experienced a significant decrease in monoclonal B cell lymphocytosis. Fifty-nine percent of patients had adverse events, although they were generally mild.

"Interferon-free, guideline-tailored therapy with DAA is highly effective and safe for HCV-associated MC patients," the authors write. "The overall 100 percent rate of clinical response of vasculitis, on an intention-to-treat basis, opens the perspective for curing the large majority of these so far difficult-to-treat patients."

**More information:** Abstract

Full Text

Copyright © 2016 HealthDay. All rights reserved.



Citation: Interferon-free, tailored Tx beneficial in HCV-associated MC (2016, August 16) retrieved 18 July 2023 from <a href="https://medicalxpress.com/news/2016-08-interferon-free-tailored-tx-beneficial-hcv-associated.html">https://medicalxpress.com/news/2016-08-interferon-free-tailored-tx-beneficial-hcv-associated.html</a>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.